Clinical Trial Search Results
MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1
To evaluate the safety and tolerability of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD). To evaluate efficacy of MT-6402 in subjects with advanced cancer by using obje ...
Multi-center, open label, prospective study to document on-going post market safety and performance of Flexiva Pulse High Power Single-Use Laser Fibers.
Multi-center, open label, prospective study to document on-going post market safety and performance of Flexiva Pulse High Power Single-Use Laser Fibers.
Multicenter, prospective, non-interventional follow-up of braided sublaminar bands for pediatric scoliosis
This research is being done to report clinical and radiographic outcomes of braided sublaminar bands, and to assess the safety of this FDA approved Jazz system.
MyLeukoMAP Genomic Survival Prediction Assay
Heart failure (HF) can cause other organs to shut down. This process appears to involve the white blood cells of the immune system. Our data show that abnormal gene activation or suppression of white blood cells may be indicati ...
NAD-flux: Measurement of NAD+ Synthesis in Human Skeletal Muscle
Nicotinamide adenine dinucleotide (NAD) is a vitally important substance that is found in all cells of the body. Elevated levels of NAD are linked to health and well-being. The key objective of this pilot research study is to ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
You are being asked to take part in this research study because your tumor results from the NCI-COG Pediatric MATCH screening protocol make you a candidate to receive the study drug called BVD-523FB (ulixertinib) that we are te ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations
You are being asked to participate in this study because you have a relapsed or refractory tumor without a proven treatment strategy for cure. The main goal of this study is to test any good and bad effects of the ensartinib on ...
NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.
NCI-COG PEdiatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
This is a Phase 2 study of a drug called LOXO-292. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. LOXO-292 is experimental because it has not been proven t ...